Core Viewpoint - Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) is recognized as a promising investment opportunity with analysts projecting over 77% upside potential following positive results from its Phase 2b RESOLVE trial for eosinophilic esophagitis [1] Group 1: Clinical Trial Results - The 52-week follow-up data from the RESOLVE trial indicated that all patients in Cohort 6 maintained symptom improvement at week 52, with an average reduction in SDI scores of -3.7, representing a 58% decrease [2] - Management highlighted that patients who completed 52 weeks in the trial experienced durable symptom relief, which is considered clinically meaningful [2] Group 2: Analyst Ratings and Price Target - Following the trial results, Kristen Kluska from Cantor Fitzgerald reaffirmed a Buy rating on Eupraxia Pharmaceuticals Inc. with a price target of C$15.38, indicating more than 76% upside from the current price level [3] - Eupraxia Pharmaceuticals is focused on developing locally delivered, extended-release drug products utilizing its proprietary DiffuSphere technology [3]